PJPallavi Jonnalagadda

Pallavi Jonnalagadda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pallavi Jonnalagadda has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI-Enabled Digital Health Tool Implementation in Clinical Practice Settings: Umbrella Review

    by Amanda Gilbert, Angeline Gacad, Loni Parrish, Oliver Nguyen, Kea Turner, Willi L Tarver, Pallavi Jonnalagadda, Dennis Tsagli, Bowen Wu, Chenyang Lu, et al.

    Background: AI has the potential to improve clinical decision-making, efficiency, and patient outcomes, yet adoption in routine clinical practice has been slower than anticipated. While prior studies have identified factors that influence AI implementation, a comprehensive synthesis grounded in implementation science frameworks is lacking. Objective: This study aimed to qualitatively and comprehensively describe barriers and facilitators to AI implementation in clinical care settings using an implementation science determinants framework, the Consolidated Framework for Implementation Research (CFIR), and to identify AI-specific determinants not fully captured by CFIR. Methods: We conducted an umbrella review of reviews examining determinants of AI implementation in clinical practice. In accordance with the PRIOR (Preferred Reporting Items for Overviews of Reviews) reporting guidance, we systematically searched PubMed, Scopus, and CINAHL for English-language reviews published between January 2013 and July 2025. Reviews were included if they addressed barriers to and facilitators of implementing AI-enabled digital health tools in clinical care settings. Determinants were deductively mapped to the updated CFIR and inductively analyzed to identify emergent AI-specific constructs. Review quality was assessed using the Joanna Briggs Institute critical appraisal checklist, and overlap among primary studies was evaluated using the GROOVE (Graphical Representation of Overlap for Overviews) tool. Results: Twenty-two reviews published between 2021 and 2025 were included, encompassing studies conducted from 1990 to 2025. Reviews varied in design, including systematic, scoping, rapid, narrative, and literature reviews. Overall review quality was mixed, with 9 (41%) reviews rated at 100% quality and 4 (18%) at 50% or lower. Primary study overlap was slight, with a corrected covered area of 0.4%. Determinants of AI implementation were identified across all CFIR domains. Prominent barriers at the innovation level included limited evidence of clinical impact, poor interpretability, complexity, lack of adaptability, and insufficiently representative data. Facilitators included perceived relative advantage, co-design with clinicians, and evidence of local clinical benefit. At the implementer level, low AI literacy, limited confidence, time constraints, and concerns about professional displacement were common barriers, while training and technical support facilitated adoption. Inner setting barriers included inadequate infrastructure, limited resources, poor workflow compatibility, and weak governance structures. Outer setting barriers included unclear policies, laws, and liability frameworks, whereas partnerships and cross-sector collaboration were frequent facilitators. Inductively identified AI-specific determinants included transparency, trust, accountability, model bias, data governance, model maintenance, robustness, generalizability, existential threat, and concern about loss of the human element in care. Conclusions: AI implementation in clinical settings is shaped by complex, multilevel, and AI-specific determinants that extend beyond traditional digital health considerations. Implementation science frameworks can be adapted to incorporate these constructs. Tailored, theory-informed strategies addressing technical, organizational, psychological, and regulatory factors are essential to support safe, equitable, and sustainable integration of AI into clinical care.

  • Open Access

    Multilevel determinants of digital health implementation in African clinical settings: an umbrella review

    by Dennis Dela Tsagli, Estherla Bemma Twene, Amanda Gilbert, Angeline Gacad, Loni Parrish, Ankeeta Saseetharran, Nana Afia Gyapong, Oliver T. Nguyen, Kea Turner, Willi L. Tarver, et al.

  • Open Access

    Real-World Data for Predicting Rapid Relapse Triple Negative Cancer: A Study Using NCDB and EHR Data

    by Pallavi Jonnalagadda, Samilia Obeng-Gyasi, Daniel G. Stover, Barbara L. Andersen, Saurabh Rahurkar

    Background: Many patients with triple-negative breast cancer (TNBC), particularly those who are older, Black, or insured by Medicaid, do not receive guideline-concordant treatment, despite its association with up to 4x higher survival. Early identification of patients at risk for rapid relapse may enable timely interventions and improve outcomes. This study applies machine learning (ML) to real-world data to predict risk of rapid relapse in TNBC. Methods: We trained various ML models (logistic regression, decision trees, random forests, XGBoost, naïve Bayes, support vector machines) using National Cancer Database (NCDB) data and fine-tuned them using electronic health record (EHR) data from a cancer registry. Class imbalance was addressed using synthetic minority oversampling technique (SMOTE). Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristics area under the curve ROC AUC, accuracy, and F1 scores. Transfer learning, cross-validation, and threshold optimization were applied to enhance the ensemble model’s performance on clinical data. Results: Initial models trained on NCDB data exhibited high NPV but low sensitivity and PPV. SMOTE and hyperparameter tuning produced modest improvements. External testing on EHR data from a cancer registry had similar model performance. After applying transfer learning, cross-validation, and threshold optimization using the clinical data, the ensemble model achieved higher performance. The optimized ensemble model achieved a sensitivity of 0.87, specificity of 0.99, PPV of 0.90, NPV of 0.98, ROC AUC of 0.99, accuracy of 0.98, and F1-score of 0.88. This optimized model, leveraging readily available clinical data, demonstrated superior performance compared to initial NCDB-trained models and those reported in extant literature. Conclusions: Transfer learning and threshold optimization effectively adapted ML models trained on NCDB data to an independent real-world clinical dataset from a single site, producing a high-performing model for predicting rapid relapse in TNBC. This model, potentially translatable to fast health interoperability resources (FHIR)-compatible workflows, represents a promising tool for identifying patients at high risk. Future work should include prospective external validation, evaluation of integration into clinical workflows, and implementation studies to determine whether the model improves care processes such as timely patient navigation and treatment planning. Author Summary: In this study, we set out to understand which patients with triple-negative breast cancer might experience a rapid return of their disease. Many people with this aggressive form of cancer do not receive the treatments that are known to improve survival, especially patients who are older, Black, or insured through public programs. Being able to identify those at highest risk early in their care could help health teams provide timely support and ensure that patients receive the treatments they need. To do this, we used information from a large national cancer database to build computer-based models that learn from patterns in patient data. We then refined these models using real medical records from a cancer center to make sure they worked well in everyday clinical settings. After adjusting and improving the models, we developed a tool that can correctly identify most patients who are likely to have a rapid return of their cancer. Our hope is that this type of tool could eventually be built into routine care and help guide timely follow-up, support services, and treatment planning. More testing in real clinical environments will be important to understand how well the tool improves care and outcomes for patients.

  • Open Access

    Identifying Pediatric Drug Safety Knowledge Gaps: An Integrated Approach Leveraging Real‐World Data, a Biomedical Knowledge Base, and Postmarketing Surveillance Data

    by Saurabh Rahurkar, Jiayi Ouyang, Pallavi Jonnalagadda, Xiaofu Liu, Shijun Zhang, Chien‐Wei Chiang, Lei Wang, Aditi Shendre, Lang Li

    Background: Drug safety has historically been understudied in pediatric populations, rendering them “therapeutic orphans.” Pediatric drug indications and dosages are often inferred by extrapolating safety, efficacy, and dosing data from adult studies, leading to widespread off‐label use. However, this approach fails to account for age‐specific differences in disease pathophysiology and developmental pharmacokinetics (PK). Despite evidence that adverse drug events (ADEs) manifest with greater severity in pediatric populations than in adults, fewer than 50% of drugs have been systematically studied for pediatric use. The lack of robust drug safety data may result in suboptimal or harmful treatment strategies.Methods: We used a data‐driven approach that integrated three databases —including Merative MarketScan claims, the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledgebase (including 670,185 pediatric pharmacoepidemiology, PK, and clinical trial publications on 5062 drugs), the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, a postmarketing safety surveillance database), and FDA drug label data— to identify high‐impact target. High‐impact targets were defined as drugs that have a high prescription volume, limited safety evidence and high risk of serious ADEs.Results: With 229,550 prescriptions in MarketScan, only 9 studies, and almost 50 high risk serious ADEs benzonatate was identified as a high‐impact drug of concern. Serious ADEs included seizure, death, and arrhythmia with proportional reportion ratios (PRRs) ranging from 4.3 to 477.8.Conclusion: Approved in 1958, Benzonatate, a nonnarcotic antitussive agent has a limited safety evidence with only nine PE/PK publications in six decades. Moreover, it is frequently prescribed off‐label for cough relief despite questionable effectiveness, and high‐risk of serious ADEs. Our findings reveal a disconnect between clinical practice and suppporting safety evidence. As such, there is critical need to study the safety of this drug using emerging real‐world data for real‐world evidence. In summary, this study presents an approach that is systematic, objective, reproducible, and data driven to identify and prioritize drug‐ADE combinations with limited evidence.


  • Open Access

    Strategies for Tailoring Patient-Centered Technologies Across the Cancer Continuum: Protocol for a Scoping Review

    by Willi L Tarver, Diamond A Boyd, Pallavi Jonnalagadda, Mireille M Bitangacha, Timothy M Pawlik, Elizabeth Palmer Kelly, Electra D Paskett

    Background: In the United States, cancer is more prevalent in racial and ethnic minority groups and in rural-dwelling and low-income people. Compared with White people of non-Hispanic descent, Black and African American people have higher cancer mortality and Hispanic people are more likely to be diagnosed with infection-related cancers. In addition, people who live in persistent poverty areas are more vulnerable to cancer mortality. Tailoring health information technologies (HITs) can help bridge health inequities by providing these populations with relevant health information and cancer care. Cultural tailoring in health care involves adapting interventions to reflect a population’s values, history, and attitudes that influence behavior. Objective: The goals of the current study are as follows: 1) to understand what elements of tailoring HITs are most effective among different underserved populations, 2) to identify ways of incorporating these elements to improve the acceptability and effectiveness of technology-based interventions, and 3) to develop a framework to tailor HITs to underserved populations and improve engagement and acceptability. Methods: A scoping review will explore how HITs have been culturally tailored to underserved populations using PubMed, Scopus, and Web of Science database searches. Our search strategy will include terms and medical subject headings associated with the categories of cancer, HITs, tailoring, and underserved populations. We will also perform a snowball search of the references of included studies. We will include quantitative and qualitative peer-reviewed, English-language studies from the United States that examine efforts to tailor HIT interventions to improve their acceptance, use, and usability among underserved populations. Predefined inclusion and exclusion criteria will be applied for study selection. For each included study, we will extract the following data: study design, cancer type, underserved population of interest, details of the technology used, study methods, sample size, study outcomes, user acceptability, and tailoring and targeting strategies. The data will be summarized descriptively and analyzed thematically. Results: Preliminary searches following this strategy yielded a total of 784 citations (after removing duplicates) that will each be reviewed by at least 2 reviewers for inclusion. This protocol was submitted before data collection. The search strategy, citation screening, and data extraction will commence in accordance with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and the published protocol. Findings will be expected by the spring of 2026. Conclusions: There is a need to develop more accessible HITs for underserved populations. This scoping review will inform researchers, providers, and developers working on cancer-specific HITs for underserved populations, such as racial and ethnic minority groups, rural-dwelling residents, and low-income populations. By summarizing evidence on tailoring strategies by population and delivery mode, the review aims to support the development of more effective and acceptable technologies. International Registered Report Identifier (IRRID): PRR1-10.2196/73705


  • Open Access

    Strategies for Tailoring Patient-Centered Technologies Across the Cancer Continuum: Protocol for a Scoping Review (Preprint)

    by Willi L Tarver, Diamond A Boyd, Pallavi Jonnalagadda, Mireille M Bitangacha, Timothy M Pawlik, Elizabeth Palmer Kelly, Electra D Paskett

    BACKGROUND In the United States, cancer is more prevalent in racial and ethnic minority groups and in rural-dwelling and low-income people. Compared with White people of non-Hispanic descent, Black and African American people have higher cancer mortality and Hispanic people are more likely to be diagnosed with infection-related cancers. In addition, people who live in persistent poverty areas are more vulnerable to cancer mortality. Tailoring health information technologies (HITs) can help bridge health inequities by providing these populations with relevant health information and cancer care. Cultural tailoring in health care involves adapting interventions to reflect a population’s values, history, and attitudes that influence behavior. OBJECTIVE The goals of the current study are as follows: 1) to understand what elements of tailoring HITs are most effective among different underserved populations, 2) to identify ways of incorporating these elements to improve the acceptability and effectiveness of technology-based interventions, and 3) to develop a framework to tailor HITs to underserved populations and improve engagement and acceptability. METHODS A scoping review will explore how HITs have been culturally tailored to underserved populations using PubMed, Scopus, and Web of Science database searches. Our search strategy will include terms and medical subject headings associated with the categories of cancer, HITs, tailoring, and underserved populations. We will also perform a snowball search of the references of included studies. We will include quantitative and qualitative peer-reviewed, English-language studies from the United States that examine efforts to tailor HIT interventions to improve their acceptance, use, and usability among underserved populations. Predefined inclusion and exclusion criteria will be applied for study selection. For each included study, we will extract the following data: study design, cancer type, underserved population of interest, details of the technology used, study methods, sample size, study outcomes, user acceptability, and tailoring and targeting strategies. The data will be summarized descriptively and analyzed thematically. RESULTS Preliminary searches following this strategy yielded a total of 784 citations (after removing duplicates) that will each be reviewed by at least 2 reviewers for inclusion. This protocol was submitted before data collection. The search strategy, citation screening, and data extraction will commence in accordance with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and the published protocol. Findings will be expected by the spring of 2026. CONCLUSIONS There is a need to develop more accessible HITs for underserved populations. This scoping review will inform researchers, providers, and developers working on cancer-specific HITs for underserved populations, such as racial and ethnic minority groups, rural-dwelling residents, and low-income populations. By summarizing evidence on tailoring strategies by population and delivery mode, the review aims to support the development of more effective and acceptable technologies. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/73705

  • Open Access

    Patient and Provider Perspectives About the Use of Patient-Generated Health Data During Pregnancy: Qualitative Exploratory Study

    by Sarah R MacEwan, Ramona G Olvera, Pallavi Jonnalagadda, Naleef Fareed, Ann Scheck McAlearney

    Background: There is increasing interest in using patient-generated health data (PGHD) to improve patient-centered care during pregnancy. However, little research has examined the perspectives of patients and providers as they report, collect, and use PGHD to inform obstetric care. Objective: This study aims to explore the perspectives of patients and providers about the use of PGHD during pregnancy, including the benefits and challenges of reporting, collecting, and using these data, as well as considerations for expanding the use of PGHD to improve obstetric care. Methods: We conducted one-on-one interviews with 30 pregnant or postpartum patients and 14 health care providers from 2 obstetrics clinics associated with an academic medical center. Semistructured interview guides included questions for patients about their experience and preferences for sharing PGHD and questions for providers about current processes for collecting PGHD, opportunities to improve or expand the collection of PGHD, and challenges faced when collecting and using this information. Interviews were conducted by phone or videoconference and were audio recorded, transcribed verbatim, and deidentified. Interview transcripts were analyzed deductively and inductively to characterize and explore themes in the data. Results: Patients and providers described how PGHD, including physiologic measurements and experience of symptoms, were currently collected during and between in-person clinic visits for obstetric care. Both patients and providers reported positive perceptions about the collection and use of PGHD during pregnancy. Reported benefits of collecting PGHD included the potential to use data to directly inform patient care (eg, identify issues and adjust medication) and to encourage ongoing patient involvement in their care (eg, increase patient attention to their health). Patients and providers had suggestions for expanding the collection and use of PGHD during pregnancy, and providers also shared considerations about strategies that could be used to expand PGHD collection and use. These strategies included considering the roles of both patients and providers in reporting and interpreting PGHD. Providers also noted the need to consider the unintended consequences of using PGHD that should be anticipated and addressed. Conclusions: Acknowledging the challenges, suggestions, and considerations voiced by patients and providers can inform the development and implementation of strategies to effectively collect and use PGHD to support patient-centered care during pregnancy.


  • Open Access

    A review of recent advances in the use of complex metal nanostructures for biomedical applications from diagnosis to treatment

    by Maryam Hajfathalian, Katherine J. Mossburg, Allan Radaic, Katherine E. Woo, Pallavi Jonnalagadda, Yvonne Kapila, Paul L. Bollyky, David P. Cormode

    Complex metal nanostructures represent an exceptional category of materials characterized by distinct morphologies and physicochemical properties. Nanostructures with shape anisotropies, such as nanorods, nanostars, nanocages, and nanoprisms, are particularly appealing due to their tunable surface plasmon resonances, controllable surface chemistries, and effective targeting capabilities. These complex nanostructures can absorb light in the near‐infrared, enabling noteworthy applications in nanomedicine, molecular imaging, and biology. The engineering of targeting abilities through surface modifications involving ligands, antibodies, peptides, and other agents potentiates their effects. Recent years have witnessed the development of innovative structures with diverse compositions, expanding their applications in biomedicine. These applications encompass targeted imaging, surface‐enhanced Raman spectroscopy, near‐infrared II imaging, catalytic therapy, photothermal therapy, and cancer treatment. This review seeks to provide the nanomedicine community with a thorough and informative overview of the evolving landscape of complex metal nanoparticle research, with a specific emphasis on their roles in imaging, cancer therapy, infectious diseases, and biofilm treatment.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Diagnostic Tools > Diagnostic Nanodevices


  • Open Access

    Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App Into Care of Patients With Cancer: Qualitative Study of Patient and Provider Perspectives

    by Megan E Gregory, Weidan Cao, Saurabh Rahurkar, Pallavi Jonnalagadda, James C Stock, Sanam M Ghazi, Endia Reid, Abigail L Berk, Courtney Hebert, Lang Li, et al.

    Background: Cardiotoxicity is a limitation of several cancer therapies and early recognition improves outcomes. Symptom-tracking mobile health (mHealth) apps are feasible and beneficial, but key elements for mHealth symptom-tracking to indicate early signs of cardiotoxicity are unknown. Objective: We explored considerations for the design of, and implementation into a large academic medical center, an mHealth symptom-tracking tool for early recognition of cardiotoxicity in patients with cancer after cancer therapy initiation. Methods: We conducted semistructured interviews of >50% of the providers (oncologists, cardio-oncologists, and radiation oncologists) who manage cancer treatment-related cardiotoxicity in the participating institution (n=11), and either interviews or co-design or both with 6 patients. Data were coded and analyzed using thematic analysis. Results: Providers indicated that there was no existing process to enable early recognition of cardiotoxicity and felt the app could reduce delays in diagnosis and lead to better patient outcomes. Signs and symptoms providers recommended for tracking included chest pain or tightness, shortness of breath, heart racing or palpitations, syncope, lightheadedness, edema, and excessive fatigue. Implementation barriers included determining who would receive symptom reports, ensuring all members of the patient’s care team (eg, oncologist, cardiologist, and primary care) were informed of the symptom reports and could collaborate on care plans, and how to best integrate the app data into the electronic health record. Patients (n=6, 100%) agreed that the app would be useful for enhanced symptom capture and education and indicated willingness to use it. Conclusions: Providers and patients agree that a patient-facing, cancer treatment-related cardiotoxicity symptom-tracking mHealth app would be beneficial. Additional studies evaluating the role of mHealth as a potential strategy for targeted early cardioprotective therapy initiation are needed.